The Food and Drug Administration (FDA) has officially submitted a proposed "interim access policy" concerning peptides to the White House for review. According to government filings, this policy would potentially permit compounding pharmacies to manufacture and distribute specific peptides that have previously been restricted by the agency.

Peptides are chains of amino acids that have gained significant attention in recent health discussions, particularly regarding their use in wellness and therapeutic treatments. The push for broader access to these compounds has been linked to Robert F. Kennedy Jr., who has advocated for changes to how the FDA regulates these substances.

While the specific details of the interim policy remain under review, the proposal represents a potential shift in how compounding pharmacies operate in relation to peptide production. Currently, the FDA has maintained strict oversight on these compounds, citing safety and efficacy concerns. The submission to the White House indicates that the administration is now evaluating whether to relax these restrictions to allow for temporary, broader access. The outcome of this review process will determine whether compounding pharmacies can legally supply these products to patients who have previously faced difficulty obtaining them through standard regulatory channels.